Haptoglobin polymorphism as a prognostic biomarker for peptide vaccine efficacy in cancer patients

2016 Fiscal Year Final Research Report

• Project/Area Number: 26430148
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor diagnostics
• Research Institution: Kurume University
• Principal Investigator: Shichijo Shigeki 久留米大学, がんワクチンセンター, 准教授 (30080592)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: ハプトグロビン / サイトカイン / ペプチドワクチン / SNPs / がん

Outline of Final Research Achievements

Hp in various types of cancer, in plasma Cytokines measured by Luminex. Above the median for each Hp of prostate cancer, stomach cancer, bladder cancer and urinary tract cancer, and esophageal cancer and less than in survival compared each P < short lifetime highs set at 0.05. On the other hand, showed no significant difference in the biliary tract cancer, lung cancer, breast cancer, brain tumors. In Hp SNPs, overall survival time of A type shorter than that of type G, while A/G type and other difference was recognized.
In addition, cancer suggests that survival differences of species and treatment methods and related cytokines is different. More than cancer suggests that by plasma Hp becomes a prognostic factor.

Free Research Field

腫瘍免疫学